VivaVision Biotech (Zhejiang) Co., Ltd., an ophthalmology-focused biotech company founded in 2016, has submitted its IPO prospectus to the Hong Kong Stock Exchange. The company, advancing two core products in Phase 3 trials—VVN461(HD) for non-infectious anterior uveitis (NIAU) and VVN001 for dry eye disease (DED)—seeks to capitalize on its dual-target JAK1/TYK2 inhibitor and second-generation LFA-1 antagonist platforms to address significant unmet needs in anterior and posterior ocular diseases.
China launch; hospital ophthalmology and retail pharmacy distribution
2028
Global Expansion
US/EU IND submissions; partnership discussions
2027+
Forward‑Looking Statements This brief contains forward‑looking statements regarding VivaVision Biotech’s Hong Kong IPO completion, Phase 3 clinical outcomes, and ophthalmology market penetration. Actual results may differ due to competitive dynamics with Novartis and AbbVie in dry eye, JAK inhibitor safety profile in ocular use, and regulatory approval timelines.-Fineline Info & Tech
By Fineline Cube 